Skip to main content
. 2014 May 28;12:149. doi: 10.1186/1479-5876-12-149

Table 1.

Clinicopathologic characteristics of patients according to breast cancer phenotype

Parameter Total (n =721) (%) Luminal A (n =303) (%) Luminal B (n =169) (%) HER-2 (n =71) (%) TNBC (n =178) (%) P -value
Age (years)
  
  
  
  
  
 0.012
  ≤50
 428 (59.4)
 173 (57.1)
 113 (66.9)
 32 (45.1)
 110 (61.8)
  
  >50
 293 (40.6)
 130 (42.9)
 56 (33.1)
 39 (54.9)
 68 (38.2)
  
Histologic grade
  
  
  
  
  
 <0.001
  I/II
 485 (67.3)
 275 (90.8)
 112 (66.3)
 37 (52.1)
 61 (34.3)
  
  III
 236 (32.7)
 28 (9.2)
 57 (33.7)
 34 (47.9)
 117 (65.7)
  
Tumor stage
  
  
  
  
  
 0.002
  T1
 355 (49.2)
 169 (55.8)
 86 (50.9)
 32 (45.1)
 68 (38.2)
  
  T2/T3
 366 (50.8)
 134 (44.2)
 83 (49.1)
 39 (54.9)
 110 (61.8)
  
Nodal metastasis
  
  
  
  
  
 0.162
  Absent
 427 (59.2)
 173 (57.1)
 93 (55.0)
 44 (62.0)
 117 (65.7)
  
  Present
 294 (40.8)
 130 (42.9)
 76 (45.0)
 27 (38.0)
 61 (34.3)
  
Estrogen receptor status
  
  
  
  
  
 <0.001
  Negative
 259 (35.9)
 5 (1.7)
 5 (3.0)
 71 (100.0)
 178 (100.0)
  
  Positive
 462 (64.1)
 298 (98.3)
 164 (97.0)
 0 (0.0)
 0 (0.0)
  
Progesterone receptor status
  
  
  
  
  
 <0.001
  Negative
 347 (48.1)
 50 (16.5)
 48 (28.4)
 71 (100.0)
 178 (100.0)
  
  Positive
 374 (51.9)
 253 (83.5)
 121 (71.6)
 0 (0.0)
 0 (0.0)
  
HER-2 status
  
  
  
  
  
 <0.001
  Negative
 565 (78.4)
 303 (100.0)
 84 (49.5)
 0 (0.0)
 178 (100.0)
  
  Positive
 156 (21.6)
 0 (0.0)
 85 (50.3)
 71 (100.0)
 0 (0.0)
  
Ki-67 LI (%)
  
  
  
  
  
 <0.001
  ≤14
 409 (56.7)
 303 (100.0)
 49 (29.0)
 29 (40.8)
 28 (15.7)
  
  >14
 312 (43.3)
 0 (0.0)
 120 (71.0)
 42 (59.2)
 150 (84.3)
  
Tumor recurrence
 63 (8.7)
 15 (5.0)
 13 (7.7)
 11 (15.5)
 24 (13.5)
 0.002
No. of patient deaths
 61 (8.5)
 13 (4.3)
 13 (7.7)
 11 (15.5)
 24 (13.5)
 0.001
Duration of clinical follow-up (months, mean ± SD) 69.9 ± 31.2 71.9 ± 29.0 70.0 ± 30.1 66.1 ± 34.9 68.1 ± 34.1 0.419

Bold number represents p<0.05.

TNBC, triple negative breast cancer.